首页> 外文期刊>Rheumatology >A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus.
【24h】

A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus.

机译:一名患有系统性红斑狼疮的肿瘤坏死因子受体相关周期性综合征(TRAPS)的日本患者的编码肿瘤坏死因子受体超家族1A(TNFRSF1A)的基因中的新型突变(T61I)。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: To identify potential mutations in the tumour necrosis factor receptor superfamily 1A gene (TNFRSF1A) in a Japanese female patient with recurrent fever complicated by systemic lupus erythematosus (SLE), and in her family members. METHODS: DNA sequencing of exons 1-10 of the TNFRSF1A gene was performed to determine mutations that might be associated with the tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Moreover, the TNFRSF1A gene was examined in Japanese patients with autoimmune diseases, including SLE, rheumatoid arthritis (RA), mixed connective tissue disease (MCTD) and Behcet's disease, and in healthy Japanese controls. Enzyme-amplified sensitivity immunoassay (EASIA) analysis was used to assess serum levels of TNF, the 55-kDa TNF receptor (TNFRSF1A) and the 75-kDa TNF receptor (TNFRSF1B). Membrane TNFRSF1A expression was analysed on the surface of peripheral blood mononuclear cells by flow cytometry. RESULTS: A novel mutation, a heterozygous C to T transition in exon 3 which substitutes an isoleucine for a threonine at position 61 (T61I) was detected in the TNFRSF1A gene derived from the genomic DNA of a Japanese female TRAPS patient. Two nieces and one nephew, all with a similar clinical phenotype, also possessed the same TNFRSF1A mutation. We further demonstrated the same mutation in five of 60 SLE patients (8.3%) and in five of 120 healthy individuals (4.2%), with no significant differences. Although high titres of serum TNF and soluble TNFRSF1B protein were observed in this patient, low titres of soluble TNFRSF1A protein were detected. However, a defect in TNFRSF1A shedding in vitro was not observed in monocytes derived from this patient. CONCLUSION: This is the first report of a TRAPS patient associated with SLE with a novel TNFRSF1A mutation (T61I).
机译:目的:确定一名日本复发性发热并发系统性红斑狼疮(SLE)女性患者及其家人的肿瘤坏死因子受体超家族1A基因(TNFRSF1A)的潜在突变。方法:对TNFRSF1A基因外显子1-10进行DNA测序,以确定可能与肿瘤坏死因子受体相关的周期性综合征(TRAPS)相关的突变。此外,在患有自身免疫性疾病(包括SLE,类风湿性关节炎(RA),混合性结缔组织病(MCTD)和白塞氏病)的日本患者以及健康的日本对照中检查了TNFRSF1A基因。酶放大敏感性免疫分析(EASIA)分析用于评估TNF,55 kDa TNF受体(TNFRSF1A)和75 kDa TNF受体(TNFRSF1B)的血清水平。通过流式细胞术分析外周血单个核细胞表面的膜TNFRSF1A表达。结果:在源自日本女性TRAPS患者基因组DNA的TNFRSF1A基因中,检测到一个新的突变,即外显子3的C到T杂合,用异亮氨酸替代61位的苏氨酸(T61I)。具有相同临床表型的两个侄女和一个侄子也具有相同的TNFRSF1A突变。我们进一步证明,在60名SLE患者中有5名(8.3%)和120名健康个体中有5名(4.2%)具有相同的突变,没有显着差异。尽管在该患者中观察到高滴度的血清TNF和可溶性TNFRSF1B蛋白,但检测到低滴度的可溶性TNFRSF1A蛋白。但是,在该患者的单核细胞中未观察到体外TNFRSF1A脱落的缺陷。结论:这是TRAPS患者与SLE伴有新的TNFRSF1A突变(T61I)的首次报道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号